Today: 7 February 2026
Subscribe
Browse Category

NYSE:PFE News 14 January 2026 - 20 January 2026

Johnson & Johnson stock heads into earnings after a mild dip — what could move JNJ next

Johnson & Johnson stock heads into earnings after a mild dip — what could move JNJ next

Johnson & Johnson shares closed down 0.4% at $218.66 Friday ahead of the Martin Luther King Jr. Day market holiday. The S&P 500 health care sector fell 0.8%. J&J reports fourth-quarter results Wednesday, Jan. 21, with investors focused on earnings and 2026 guidance. The NYSE will reopen Tuesday after the holiday.
18 January 2026
··········
Pfizer stock slips into MLK Day break as FDA fast-track fears and key dates loom

Pfizer stock slips into MLK Day break as FDA fast-track fears and key dates loom

Pfizer shares fell 0.93% to $25.65 Friday amid industry concerns over a White House-backed fast FDA review program, Reuters reported. The company reaffirmed its 2026 revenue forecast and set its next dividend at $0.43 per share, with an ex-dividend date of Jan. 23. U.S. markets will close Monday for Martin Luther King Jr. Day. Pfizer’s quarterly results are due Feb. 3.
18 January 2026
·····
Healthcare stocks slide into long weekend as XLV drops; J&J earnings loom

Healthcare stocks slide into long weekend as XLV drops; J&J earnings loom

Healthcare stocks led S&P 500 declines Friday, with XLV down 0.8% to $155.74. UnitedHealth fell 2.3%, Merck 1.9%, and Pfizer 0.9%, while Novo Nordisk surged 9.1% after early Wegovy prescription data. U.S. markets close Monday for Martin Luther King Jr. Day. Johnson & Johnson reports earnings Wednesday, January 21.
17 January 2026
··········
Pfizer stock slips into holiday week as CEO filing, vaccine-policy row and biotech IPO news land

Pfizer stock slips into holiday week as CEO filing, vaccine-policy row and biotech IPO news land

Pfizer shares closed down 0.9% at $25.65 Friday after CEO Albert Bourla disclosed a phantom-stock award and expressed frustration over U.S. vaccine policy changes. A European patent ruling kept COVID-era lawsuits in focus. Investors await Tuesday’s open after the holiday and Pfizer’s February 3 results update.
17 January 2026
·····
Pfizer stock slips into long weekend as PFE investors line up earnings, dividend dates

Pfizer stock slips into long weekend as PFE investors line up earnings, dividend dates

Pfizer shares fell 0.9% to $25.65 Friday, with trading volume near 58 million. U.S. markets will close Monday for Martin Luther King Jr. Day, reopening Tuesday. Pfizer’s ex-dividend date is Jan. 23, and its quarterly earnings report is set for Feb. 3. Investors are watching for updates on 2026 forecasts and growth plans.
17 January 2026
·····
Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

Pfizer shares rose 0.3% to $25.67 Thursday as investors weighed U.S. vaccine policy debates and the company’s growth outlook. The stock moved between $25.26 and $25.67 with 22.3 million shares traded. Pfizer will report Q4 results on Feb. 3, with guidance projecting 2026 revenue of $59.5–$62.5 billion and lower COVID-19 product sales. Competition in obesity drugs and AI-driven drug discovery remain in focus.
15 January 2026
·····
Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer shares fell 0.6% to $25.42 in late-morning trading Thursday as U.S. vaccine policy changes fueled uncertainty. Sanofi warned of weaker U.S. vaccine demand; Pfizer’s CEO criticized the new recommendations. Moderna and Merck also traded lower. Investors await Pfizer’s Feb. 3 results for updates on 2026 outlook and new product pipeline.
15 January 2026
·········
Pfizer stock rises as CEO bets on “Viagra-like” obesity demand; what investors watch next

Pfizer stock rises as CEO bets on “Viagra-like” obesity demand; what investors watch next

Pfizer shares rose 1.7% to close at $25.58 on Wednesday, driven by investor focus on its push into obesity drugs. CEO Albert Bourla said Pfizer will launch 10 Phase 3 trials for Metsera compounds this year. After-hours trading was quiet. Investors await Pfizer’s results update on Feb. 3 and the ex-dividend date on Jan. 23.
15 January 2026
···
Pfizer (PFE) stock rises as CEO calls obesity push a “Viagra”-scale bet, with earnings next in focus

Pfizer (PFE) stock rises as CEO calls obesity push a “Viagra”-scale bet, with earnings next in focus

Pfizer shares rose 2% to $25.65 Wednesday after CEO Albert Bourla said the company is “all in on obesity” and plans 10 Phase 3 trials for its Metsera compounds by 2026. Pfizer does not expect revenue growth to return until 2029 as it faces patent expirations and weaker COVID-related sales. AbbVie also announced new obesity drug plans. Novo Nordisk warned of tougher competition in 2026.
14 January 2026
····
Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings

Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings

Pfizer shares rose 1.4% to $25.51 Wednesday morning, outpacing a broader market decline. CEO Albert Bourla said the company misjudged the cash-pay obesity drug market and plans about 10 Phase 3 obesity trials in 2026. Investors are watching for Feb. 3 results and updates on late-stage trial launches. Pfizer expects no revenue growth before 2029 as it faces major patent expirations.
14 January 2026
·····
Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson shares rose 1.9% to $217.80 by late morning Wednesday, outperforming a 1% drop in the S&P 500. Delaware’s Supreme Court threw out part of a ruling tied to Auris Health merger payments, possibly cutting damages by hundreds of millions. Legal battles over talc litigation continue. J&J’s Q4 earnings call is scheduled for Jan. 21.
14 January 2026
········
1 2 3 4 5 … 10

Stock Market Today

Walmart stock jumps to $131 as traders brace for CPI and Feb. 19 earnings

Walmart stock jumps to $131 as traders brace for CPI and Feb. 19 earnings

7 February 2026
Walmart shares rose 3.3% Friday to $131.18, up 10% since Jan. 30, as the Dow closed above 50,000 for the first time. The retailer’s market value crossed $1 trillion this week. Investors await January inflation data on Feb. 13 and Walmart’s quarterly results on Feb. 19 for signs of continued momentum.
Caterpillar stock price jumps 7% to $726 as Dow cracks 50,000 — what matters next week

Caterpillar stock price jumps 7% to $726 as Dow cracks 50,000 — what matters next week

7 February 2026
Caterpillar shares surged 7.1% to $726.20 Friday, driving the Dow above 50,000 for the first time. The move erased recent losses and followed insider selling by Group President Bob De Lange earlier in the week. Deere and CNH Industrial also gained as investors rotated into industrial stocks. Markets await next week’s U.S. jobs and inflation data.
Amazon stock slides as $200B AI spending plan meets cautious profit outlook

Amazon stock slides as $200B AI spending plan meets cautious profit outlook

7 February 2026
Amazon shares fell 9% Friday after the company announced plans for $200 billion in 2026 capital spending, mainly for AWS and AI, and issued a first-quarter profit outlook below estimates. The stock drop could erase $200 billion in market value. Fourth-quarter net sales rose 14% to $213.4 billion, while free cash flow declined due to higher spending on AI infrastructure.
Go toTop